.svg){kind=small}
Sep-2026
Sales
Trend
6-Month
Product Count
SKUs
Avg Price
YoY Sales Change
YoY Price Change
Market Insights Snapshot
MediPharm Labs concentrated 91.88% of September 2026 sales in Oil, where year-over-year sales fell 25.98% but month-over-month inched up 0.91%, while Vapor Pens held 6.07% share with a 53.34% YoY decline and a 0.09% MoM uptick. Capsules represented 1.64% share with a 16.12% YoY decline yet a 33.04% MoM jump, and Edible slid to 0.41% share with a 93.36% YoY drop and a 64.45% MoM contraction. With average price down 3.22% YoY to $41.51 and ON as the leading province, the pattern implies a deliberate defense of the Oil core alongside tactical testing in Capsules, while retreating from Edible limits diversification risk but concentrates exposure to a single category cycle.
Holding rank 1 in Oil in Alberta indicates category leadership even as overall brand sales declined 31.15% YoY and 47.73% versus 24 months, suggesting pricing power and distribution depth are anchored in Oil rather than portfolio breadth. The simultaneous 0.91% MoM lift in Oil and 33.04% MoM gain in Capsules point to near-term momentum concentrated in medically oriented formats, while the 53.34% YoY decline in Vapor Pens and 93.36% YoY erosion in Edible imply a de-prioritized lifestyle segment; this mix implies MediPharm Labs’ positioning is skewing toward clinically aligned, higher-trust use cases where sustaining rank advantages in Oil can offset category volatility more effectively than chasing share in declining peripheral categories.
Competitive Landscape
MediPharm Labs sits at rank #3 in ON Oil in September 2026, unchanged from #3 year over year, with a prior peak at #2 in December 2024 and no movement from #3 over the past three months, while category leaders are shifting around it: Mod held #1 both year over year and currently with sales up 3.16%, and Redecan stayed at #2 year over year despite a 21.22% sales decline, indicating that the gap above #3 may be more about competitors sliding than new share capture; below, NightNight remains #4 with sales down 1.44% and ufeelu sits #5 after improving from #6 year over year with sales down 5.38%, suggesting MediPharm Labs’ flat ranking at #3 amid both a 1-rank improvement by a follower and a 21.22% contraction in the #2 competitor implies a plateau that depends on defending share rather than organic upward momentum.
Notable Products
CBN/CBD 1:2 Relax Formula Oil (30ml) posted the steepest decline at -18.96% and slipped to rank 3, while THC 30 Regular Formula Oil (30ml) fell -7.98% at rank 2. In contrast, CBN:THC 1:2 Nighttime Formula Oil (30ml) grew 19.05% and holds rank 1, and High CBD Distillate Disposable (1g) gained 20.30% at rank 6, indicating momentum outside core Oils. With eight of the top ten in Oils and CBD:THC 25:1 Ultra Formula Oil ( 3000mg CBD, 120mg THC ,30ml) down -25.61% at rank 8 against Nighttime’s growth, mix is tilting toward sleep-focused CBN formulations over high-CBD tinctures; September 2026 revenue concentration remains anchored by Oils despite the $23,016 in the Vapor Pens entrant. The pattern implies MediPharm Labs is pivoting toward effect-led Oils, particularly CBN-driven sleep solutions, while cautiously expanding into inhalable CBD to diversify beyond tinctures.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
